Cargando…
Synthesis and Comparative In Vivo Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET
[Image: see text] Delta-like ligand 3 (DLL3) is a therapeutic target for the treatment of small cell lung cancer, neuroendocrine prostate cancer, and isocitrate dehydrogenase mutant glioma. In the clinic, DLL3-targeted (89)Zr-immunoPET has the potential to aid in the assessment of disease burden and...
Autores principales: | Sharma, Sai Kiran, Adumeau, Pierre, Keinänen, Outi, Sisodiya, Vikram, Sarvaiya, Hetal, Tchelepi, Robert, Korsen, Joshua A, Pourat, Jacob, Edwards, Kimberly J., Ragupathi, Ashwin, Hamdy, Omar, Saunders, Laura R., Rudin, Charles M., Poirier, John T., Lewis, Jason S., Zeglis, Brian M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2021
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295218/ https://www.ncbi.nlm.nih.gov/pubmed/33835770 http://dx.doi.org/10.1021/acs.bioconjchem.1c00121 |
Ejemplares similares
-
Visualizing
Galectin-3 Binding Protein Expression
with ImmunoPET
por: Keinänen, Outi, et al.
Publicado: (2023) -
(89)Zr-Labeled AR20.5: A MUC1-Targeting ImmunoPET Probe
por: Fung, Kimberly, et al.
Publicado: (2020) -
ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody
por: Sharma, Sai Kiran, et al.
Publicado: (2022) -
Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for (89)Zr-immunoPET
por: Raavé, René, et al.
Publicado: (2019) -
Imaging PD-L1 Expression with ImmunoPET
por: Truillet, Charles, et al.
Publicado: (2017)